Notice: This company has been marked as potentially delisted and may not be actively trading. NantKwest (NK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends NK vs. NVAX, VIR, ADPT, REPL, PSTX, DNA, OPT, AVXL, LENZ, and RLAYShould you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Novavax (NVAX), Vir Biotechnology (VIR), Adaptive Biotechnologies (ADPT), Replimune Group (REPL), Poseida Therapeutics (PSTX), Ginkgo Bioworks (DNA), Opthea (OPT), Anavex Life Sciences (AVXL), LENZ Therapeutics (LENZ), and Relay Therapeutics (RLAY). These companies are all part of the "medical" sector. NantKwest vs. Novavax Vir Biotechnology Adaptive Biotechnologies Replimune Group Poseida Therapeutics Ginkgo Bioworks Opthea Anavex Life Sciences LENZ Therapeutics Relay Therapeutics Novavax (NASDAQ:NVAX) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk. Does the MarketBeat Community believe in NVAX or NK? Novavax received 577 more outperform votes than NantKwest when rated by MarketBeat users. Likewise, 74.11% of users gave Novavax an outperform vote while only 49.91% of users gave NantKwest an outperform vote. CompanyUnderperformOutperformNovavaxOutperform Votes85074.11% Underperform Votes29725.89% NantKwestOutperform Votes27349.91% Underperform Votes27450.09% Do institutionals & insiders believe in NVAX or NK? 53.0% of Novavax shares are owned by institutional investors. Comparatively, 9.4% of NantKwest shares are owned by institutional investors. 1.0% of Novavax shares are owned by insiders. Comparatively, 71.7% of NantKwest shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer NVAX or NK? Novavax presently has a consensus target price of $17.83, indicating a potential upside of 123.20%. Given Novavax's stronger consensus rating and higher probable upside, analysts plainly believe Novavax is more favorable than NantKwest.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novavax 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33NantKwest 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is NVAX or NK more profitable? Novavax has a net margin of -32.18% compared to NantKwest's net margin of -76,658.58%. Novavax's return on equity of 0.00% beat NantKwest's return on equity.Company Net Margins Return on Equity Return on Assets Novavax-32.18% N/A -17.05% NantKwest -76,658.58%-56.06%-46.93% Does the media favor NVAX or NK? In the previous week, Novavax had 8 more articles in the media than NantKwest. MarketBeat recorded 8 mentions for Novavax and 0 mentions for NantKwest. Novavax's average media sentiment score of 0.51 beat NantKwest's score of 0.00 indicating that Novavax is being referred to more favorably in the media. Company Overall Sentiment Novavax Positive NantKwest Neutral Which has more volatility & risk, NVAX or NK? Novavax has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, suggesting that its stock price is 161% more volatile than the S&P 500. Which has higher earnings & valuation, NVAX or NK? NantKwest has lower revenue, but higher earnings than Novavax. NantKwest is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovavax$983.71M1.30-$545.06M-$2.26-3.54NantKwest$40K9,349.00-$65.79M-$0.70-4.89 SummaryNovavax beats NantKwest on 13 of the 18 factors compared between the two stocks. Get NantKwest News Delivered to You Automatically Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NK vs. The Competition Export to ExcelMetricNantKwestBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$373.96M$3.11B$5.84B$9.15BDividend YieldN/A1.55%4.75%3.85%P/E Ratio-4.8229.6426.3819.16Price / Sales9,349.00329.47435.3370.72Price / CashN/A168.8738.0134.83Price / Book2.783.687.644.62Net Income-$65.79M-$71.72M$3.19B$246.06M NantKwest Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKNantKwestN/A$3.42-6.0%N/A-34.7%$373.96M$40,000.00-4.82160Analyst ForecastHigh Trading VolumeNVAXNovavax3.9661 of 5 stars$8.19+0.7%$17.83+117.7%+63.7%$1.31B$983.71M-3.621,543Analyst RevisionNews CoverageVIRVir Biotechnology3.1839 of 5 stars$9.38-4.7%$34.83+271.4%-7.1%$1.29B$86.18M-2.39580Insider TradeADPTAdaptive Biotechnologies3.6376 of 5 stars$7.68-2.0%$7.38-4.0%+113.1%$1.16B$177.28M-5.73790Analyst ForecastInsider TradeREPLReplimune Group4.0661 of 5 stars$13.12-5.9%$19.14+45.9%+75.8%$953.73MN/A-4.30210Gap UpPSTXPoseida Therapeutics1.0987 of 5 stars$9.50flat$9.50N/A$928.85M$150.86M-15.08260DNAGinkgo Bioworks0.8367 of 5 stars$13.48-5.4%$4.58-66.1%N/A$774.66M$251.46M-1.031,218Upcoming EarningsNews CoverageGap UpOPTOpthea2.0513 of 5 stars$5.54-3.3%$12.00+116.6%+54.0%$755.82M$120,000.000.008Upcoming EarningsGap UpAVXLAnavex Life Sciences3.7812 of 5 stars$8.81+3.5%$44.00+399.4%+66.7%$747.23MN/A-16.9440Analyst ForecastAnalyst RevisionGap UpLENZLENZ Therapeutics1.4696 of 5 stars$25.00-1.1%$35.40+41.6%N/A$687.50MN/A0.00110RLAYRelay Therapeutics1.6404 of 5 stars$4.01-5.0%$20.50+411.2%-62.9%$671.19M$25.55M-1.54330 Related Companies and Tools Related Companies NVAX Alternatives VIR Alternatives ADPT Alternatives REPL Alternatives PSTX Alternatives DNA Alternatives OPT Alternatives AVXL Alternatives LENZ Alternatives RLAY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NK) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NantKwest, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NantKwest With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.